Approaching Ewing sarcoma

Future Oncology

Volumn 6, Issue 7, 2010, Pages 1155-1162

  Dirksen, Uta ^a   Jürgens, Heribert ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Ewing sarcoma; immunotherapy; target; translation; translocation

Indexed keywords

TRANSCRIPTION FACTOR; RNA BINDING PROTEIN EWS;

CANCER CHEMOTHERAPY; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; ETS GENE; EWING SARCOMA; EWS GENE; GENE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW; SURVIVAL RATE; TRANSLATION REGULATION; TUMOR IMMUNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; RESEARCH; SARCOMA, EWING; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; TRENDS;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RESEARCH; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; SARCOMA, EWING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 77954685904     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.76     Document Type: Review

References (45)

1. Gurney JG, Swensen AR, Bulterys M: Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents. United States SEER Program 1975-1999. Ries LAG, Smith MA, Gurney JG, et al. (Eds). National Institutes of Health, Bethesda, MD, USA, 99-110 (1999).
2. Pieper S, Ranft A, Braun-Munzinger G, Jurgens H, Paulussen M, Dirksen U: Ewings tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie 31(12), 657-663 (2008).
3. Paulussen M, Ranft A, Dirksen U, Jurgens H: Ewing tumours: outcome in children, adolescents and adult patients. Eur. J. Cancer Suppl. (5), 209-215 (2007).
4. Paulussen M, Craft AW, Lewis I, et al.: Results of the EICESS-92 Study: two randomized trials of Ewings sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. European Intergroup Cooperative Ewings Sarcoma Study-92. J. Clin. Oncol. 26(27), 4385-4393 (2008).
5. Granowetter L, Womer R, Devidas M, et al.: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Childrens Oncology Group Study. J. Clin. Oncol. 27(15), 2536-2541 (2009).
6. Haeusler J, Ranft A, Bölling T, et al.: The value of local treatment in patients with primary, disseminated multifocal Ewing sarcoma (PDMES). Cancer 116(2), 443-450 (2010).
7. Leavey PJ, Mascarenhas L, Marina N, et al.: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Childrens Oncology Group. Childrens Oncology Group. Pediatr. Blood Cancer 51(3), 334-338 (2008).
8. Zucman J, Melot T, Desmaze C, et al.: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12(12), 4481-4487 (1993).
9. Le Deley MC, Delattre O, Schäfer KL, et al.: Impact of EWS-ETS fusion type on disease progression in Ewinǵs sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative EURO-E.W.I.N.G.99 trial. J. Clin. Oncol 28(12), 1982-1888 (2010).
10. Maksimenko A, Malvy C: Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin. Ther. Targets 9(4), 825-830 (2005).
11. Elhamess H, Bertrand JR, Maccario J, Maksimenko A, Malvy C: Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles. Oligonucleotides 19(3), 255-264 (2009).
12. Gangwal K, Sankar S, Hollenhorst PC, et al.: Microsatellites as EWS/FLI response elements in Ewings sarcoma. Proc. Natl Acad. Sci. USA 105(29), 10149-10154 (2008).
13. Kauer M, Nan J, Kofler R, et al.: A molecular function map of Ewing̀s sarcoma. PLoS ONE 4(e5415), 1-11 (2009).
14. Hancock JD, Lessnick SL: A transcriptional profiling meta-analysis reveals a core EWS-FLI1 gene expression signature. Cell Cycle 7(2), 250-256 (2008).
15. Richter GHS, Plehm S, Fasan A, et al.: EZH2 is a mediator of EWS/Fli1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. PNAS 106(13), 5324-5329 (2009).
16. Riggi N, Suvà ML, Suvà D, et al.: EWS-Fli1 expression triggers a Ewing sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 68(7), 2176-2185 (2008).
17. Owen LA, Kowalewski AA, Lessnick SL: EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewings sarcoma PLoS ONE 3(4e1965), 1-7 (2008).
18. Joo J, Christensen L, Warner K, et al.: GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 4(10e7608), 1-9 (2009).
19. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases and their signal transduction pathways. Ann. Rev. Cell Biol. 10, 251-337 (1994).
20. Gwschind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4(1), 361-370 (2004). (Pubitemid 38579482)
21. Prieur A, Tirode F, Cohen P, Delattre O: EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24(16), 7275-7283 (2004).
22. Tolcher AW, Sarantopoulos J, Patnaik A, et al.: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27(34), 5800-5807 (2009).
23. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ: The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 69(19), 7662-7671 (2009).
24. Chugh R, Wathen KJ, Maki RG, et al.: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J. Clin. Oncol. 27(7), 3148-3153 (2009).
25. Do I, Araujo ES, Kalil RK, et al.: Protein expression of KIT and gene mutation of c-Kit and PDGFRs in Ewing sarcomas. Pathol. Res. Pract. 203(1), 486-492 (2007).
26. Ikeda AK, Judelson DR, Federman N, et al.: ABT-869 inhibits the proliferation of Ewing sarcoma cells and suppresses platelet-derived growth factor receptor b and c-KIT signalling pathways. Mol. Cancer Ther. 9(3), 653-660 (2010).
27. Wullschleger S, Loewith R, Hall MN: TOR signalling in growth and metabolism. Cell 124(3), 471-484 (2006).
28. Mateo-Lozano, S, Tirado OM, Notario V: Rapamycin induces the fusion-type independent downregulation of the EWS-Fli1 proteins and inhibits Ewings sarcoma cell proliferation. Oncogene 22(3), 9282-9287 (2003).
29. Erkizan HV, Kong Y, Merchant M, et al.: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewings sarcoma. Nat. Med. 15(7), 750-756 (2009).
30. Roberts P, Burchill SA, Brownhill S, et al.: Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing̀s sarcoma family of tumors. Genes Chromosomes Cancer 47(4), 207-220 (2007).
31. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J: Advances in Ewing̀s sarcoma research: where are we now and what lies ahead? Cancer Res. 69(18), 7140-7150 (2009).
32. Berghuis D, de Hooge AS, Santos SJ, et al.: Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J. Pathol. 218(2), 222-231 (2009).
33. Brinkrolf P, Landmeier S, Altvater B, et al.: A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25(hi) FoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int. J. Cancer 125(4), 879-886 (2009).
34. Verhoeven DH, de Hooge AS, Mooiman EC, et al.: NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Pediatr. Transplant. 13(6), 746-753 (2008).
35. Macall CL, Rhea EH, Read EJ, et al.: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin. Cancer Res. 14(15), 4850-4880 (2008).
36. Lissat A, Vraetz T, Tsokos M, et al.: Interferon g sensitizes resistant Ewings sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am. J. Pathol. 170, 1917-1930 (2007).
37. Tomek S, Koestler W, Horak P, et al.: TRAIL-induced apoptosis and interaction with cyctotoxic agents in soft tissue sarcoma cell lines. Eur. J. Cancer 39(2), 1318-1329 (2003).
38. Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27(3), 6297-16215 (2008).
39. Scotlandi K, Perdichizzi S, Bernard G, et al.: Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewings sarcoma. Eur. J. Cancer 42(1), 91-96 (2006).
40. Zucman-Rossi J, Batzer MA, Stoneking M, et al.: Interethnic polymorphism of EWS intron 6: menome plasticity mediated by Alu reposition and recombination. Hum. Genet. 99, 357-363 (1997).
41. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois SG: Ethnic and racial differences in patients with Ewing sarcoma. Cancer 2(15), 983-988 (2010).
42. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP: Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome. Cancer 115(15), 3526-3536 (2009).
43. Bacci G, Ferrari S, Bertoni F, et al.: Prognostic factors in nonmetastatic Ewings sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J. Clin. Oncol. 18(1), 4-11 (2000).
44. Craft AW, Cotterill S, Imeson J: Improvement in survival for Ewing̀s sarcoma by substitution of ifosfamide for cyclophosphamide: a UKCCSG/MRC study. Am. J. Pediatr. Hematol. Oncol. 15(1), 31-35 (1993).
45. Paulussen M, Ahrens S, Burdach S, et al.: Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann. Oncol. 9, 275-281 (1998).